p.(L576P) -KIT mutation in GIST: Favorable prognosis and sensitive to imatinib?

References

• Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279:577-80; PMID:9438854; http://dx.doi.org/10.1126/science.279.5350.577
   PubMed Web of Science ®Google Scholar
• van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001; 358:1421-3; PMID:11705489; http://dx.doi.org/10.1016/S0140-6736(01)06535-7
   PubMed Web of Science ®Google Scholar
• Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008; 26:626-32; PMID:18235122; http://dx.doi.org/10.1200/JCO.2007.13.4452
   PubMed Web of Science ®Google Scholar
• Demetri G, von Mehren M, Blanke C, Van den Abbeele AD, Eisenberg B, Roberts P, Heinrich MC, Tuveson DA, Singer S, Janicek M, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347:472-80; PMID:12181401; http://dx.doi.org/10.1056/NEJMoa020461
   PubMed Web of Science ®Google Scholar
• Corless CL, McGreevey L, Town A, Schroeder A, Bainbridge T, Harrell P, Fletcher JA, Heinrich MC. KIT gene deletions at the intron 10-exon 11 boundary in GI stromal tumors. J Mol Diagn 2004; 6:366-70; PMID:15507676; http://dx.doi.org/10.1016/S1525-1578(10)60533-8
   PubMed Web of Science ®Google Scholar
• Conca E, Negri T, Gronchi A, Fumagalli E, Tamborini E, Pavan GM, Fermeglia M, Pierotti MA, Pricl S, Pilotti S. et al. Activate and resist: L576P-KIT in GIST. Mol Cancer Ther 2009; 8:2491-5; PMID:19723893; http://dx.doi.org/10.1158/1535-7163.MCT-09-0662
   PubMed Web of Science ®Google Scholar
• Joensuu H, Rutkowski P, Nishida T, Steigen S, Brabec P, Plank L, Nilsson B, Braconi C, Bordoni A, Magnusson MK, et al. KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence. J Clin Oncol 2015; 33:634-42; PMID:25605837; http://dx.doi.org/10.1200/JCO.2014.57.4970
   PubMed Web of Science ®Google Scholar
• Miettinen M, Sobin L, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005; 29:52-68; PMID:15613856; http://dx.doi.org/10.1097/01.pas.0000146010.92933.de
   PubMed Web of Science ®Google Scholar
• Joensuu H, Eriksson M, Sundby Hall K, Hartmann J, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 2012; 307:1265-72; PMID:22453568; http://dx.doi.org/10.1001/jama.2012.347
   PubMed Web of Science ®Google Scholar
• Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B, Leversha MA, Jeffrey PD, Desantis D, Singer S, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005; 11:4182-90; PMID:15930355; http://dx.doi.org/10.1158/1078-0432.CCR-04-2245
   PubMed Web of Science ®Google Scholar
• Antonescu C, Busam K, Francone T, Wong G, Guo T, Agaram N, Jungbluth A, Gimbel M, Chen CT, et al. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer 2007; 121:257-64; PMID:17372901; http://dx.doi.org/10.1002/ijc.22681
   PubMed Web of Science ®Google Scholar
• Carvajal R, Antonescu C, Wolchok J, Chapman P, Roman R-A, Teitcher J, Panageas KS, Busam KJ, Chmielowski B, Lutzky J, et al. KIT as a therapeutic target in metastatic melanoma. JAMA 2011; 305:2327-34; PMID:21642685; http://dx.doi.org/10.1001/jama.2011.746
   PubMed Web of Science ®Google Scholar
• Gounder M, Maki R. Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor. Cancer Chemother Pharmacol 2011; 67(Suppl 1):S25-43; PMID:21116624; http://dx.doi.org/10.1007/s00280-010-1526-3
   PubMedGoogle Scholar
• Demetri G, Wang Y, Wehrle E, Racine A, Nikolova Z, Blanke C, Joensuu H, von Mehren M. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol 2009; 27:3141-7; PMID:19451435; http://dx.doi.org/10.1200/JCO.2008.20.4818
   PubMed Web of Science ®Google Scholar
• Miranda C, Nucifora M, Molinari F, Conca E, Anania M, Bordoni A, Saletti P, Mazzucchelli L, Pilotti S, Pierotti MA, et al. KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. Clin Cancer Res 2012; 18:1769-76; PMID:22282465; http://dx.doi.org/10.1158/1078-0432.CCR-11-2230
   PubMed Web of Science ®Google Scholar
• Quattrone A, Wozniak A, Dewaele B, Floris G, Vanspauwen V, Van Looy T, Schöffski P, Rutkowski P, Sciot R, Debiec-Rychter M.. Frequent mono-allelic loss associated with deficient PTEN expression in imatinib-resistant gastrointestinal stromal tumors. Mod Pathol 2014; 27:1510-20; PMID:24743220; http://dx.doi.org/10.1038/modpathol.2014.53
   PubMed Web of Science ®Google Scholar
• Romeo S, Debiec Rychter M, Van Glabbeke M, Van Paassen H, Comite P, Van Eijk R, Oosting J, Verweij J, Terrier P, Schneider U, et al. Cell cycle/apoptosis molecule expression correlates with imatinib response in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res 2009; 15:4191-8; PMID:19509155; http://dx.doi.org/10.1158/1078-0432.CCR-08-3297
   PubMed Web of Science ®Google Scholar
• Saponara M, Urbini M, Astolfi A, Indio V, Ercolani G, Del Gaudio M, Santini D, Pirini MG, Fiorentino M, Nannini M, et al. Molecular characterization of metastatic exon 11 mutant gastrointestinal stromal tumors (GIST) beyond KIT/PDGFRα genotype evaluated by next generation sequencing (NGS). Oncotarget 2015; 6:42243-57; PMID:26544626; http://dx.doi.org/10.18632/oncotarget.6278
   PubMed Web of Science ®Google Scholar